HEALTHSTAT NEWS
STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
French pharma company Servier will acquire Edgewise Therapeutics’ muscular dystrophy business in a deal worth up to $2.65 billion. The acquisition centers on Edgewise’s sevasemten, an oral drug in pivotal trials for Becker muscular dystrophy and Phase 2 trials for Duchenne muscular dystrophy.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
- Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion
- GBL Backs CVC Offer to Buy Italy’s Recordati for $12 Billion
- STAT+: Roche to buy PathAI for $750 million
- STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug
- Itochu Takes Over AirLife’s Japan Sales in Healthcare Expansion